NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v. Organon & Co., et al. (Case No. 2:25-cv-05322) has been commenced in the United States District Court for the District of New Jersey ...

Company Overview - Organon & Co. is a global healthcare company primarily focused on improving women's health [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon, specifically regarding false or misleading statements made by the company and its executives [1] - The investigation is aimed at determining whether Organon failed to disclose material information to investors [1] Recent Developments - On May 1, 2025, Organon announced a significant dividend cut of approximately 90%, which led to a stock price decline of more than 28% [3]

Group 1 - Organon & Co. is initiated at Strong Buy with a price target of $26.4, highlighting its diversified portfolio in Rx therapies, particularly in women's health and biosimilars [1] - The investment thesis is supported by a forecasted operational inflection, indicating potential growth and performance improvement [1] - Moretus Research emphasizes a structured approach to equity research, focusing on companies with durable business models and mispriced cash flow potential [1] Group 2 - The research methodology combines rigorous fundamental analysis with a judgment-driven process, aiming to filter out noise and overly complex forecasting [1] - Valuation is based on sector-relevant multiples tailored to each company's business model, emphasizing comparability and simplicity [1] - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, which can lead to asymmetric returns [1]

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - Organon is a global healthcare company primarily focused on improving the health of women [2] Recent Developments - On May 1, 2025, Organon announced a dividend cut of approximately 90%, leading to a stock price decline of more than 28% [3]

Core Insights - Organon & Co. reported mixed Q1 FY25 results, with a revenue decline of 7% year-over-year to $1.51 billion, primarily due to a 17% decline in Biosimilars and an 11% drop in Established Brands following the loss of Atozet exclusivity [2] - The company announced a significant dividend cut from $0.28 to $0.02, representing a decrease of over 92%, which led to a more than 28% drop in its stock price on the same day [2] Company Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Organon on behalf of its stockholders, focusing on possible violations of federal securities laws and other unlawful business practices [1]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, inte ...

LOS ANGELES, May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. As part of its Q1 2025 earnings release, Organon announced it was slashing its quarterly dividend by approximately 90% despite pr ...

Group 1 - The law firm Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co., focusing on whether false or misleading statements were made by the company and its executives [1][2] - Organon announced a significant dividend cut of approximately 90% on May 1, 2025, which led to a stock price decline of more than 28% [3] Group 2 - Organon is identified as a global healthcare company primarily focused on improving women's health [2] - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [4]

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can prov ...

Group 1 - The Conservative Income Portfolio targets value stocks with high margins of safety and aims to reduce volatility through well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - Trapping Value and Preferred Stock Trader collaborate to provide income-generating portfolios and a bond ladder, focusing on capital preservation [3] Group 2 - Organon (NYSE: OGN) has been followed and traded by the company for a long time, with similarities noted to VTRS [2] - The Covered Calls Portfolio aims for lower volatility income investing with an emphasis on capital preservation [2] - The fixed income portfolio focuses on acquiring securities with high income potential and significant undervaluation compared to peers [2]